The content on this site is intended for healthcare professionals only
Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective
Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia
Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM
Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies
The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL
Key insights from lung cancer research at ASCO 2025
POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma
Understanding Ghana's FDA and pharmacovigilance regulations
Understanding Zimbabwe's pharmacovigilance system
ASCO 2025: Importance of early testing in metastatic prostate cancer
ASCO 2025: Expert commentary and discussion
ASCO 2025: Highlights and analysis
